Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer

Okamoto, Tatsuro; Nakamura, Tomomi; Ikeda, Jirō; Maruyama, Riichiroh; Fukushima, Shoji; Miyake, Tetsuro; Wataya, Hiroshi; Ichinose, Yukito

doi:10.1016/j.ejca.2005.03.011

Cited by 52 publications

(54 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They attributed this to a possible anti-apoptotic signal of the mutant EGFR pathway that may elevate the expression level of CEA protein. Our data are similar to the data of Okamato et al (11). Shoji et al (22) reported that the rate of the EGFR gene mutation significantly increased as the serum CEA level increased (for serum CEA levels of <5, ≥5 but <20, and ≥20, the rate of the EGFR gene mutation was 35, 55 and 87.5%, respectively; P=0.040).…”

Section: Discussionsupporting

confidence: 91%

“…On the contrary, Okamoto et al (11) reported that patients treated with EGFR TKIs with high pre-treatment levels of CEA had a longer survival and a better response than those with l-CEA. They attributed this to a possible anti-apoptotic signal of the mutant EGFR pathway that may elevate the expression level of CEA protein.…”

Section: Discussionmentioning

confidence: 96%

“…Several (6)(7)(8)(9)(10). According to recent reports, CEA and CYFRA 21-1 were significant predictors of sensitivity and survival in patients treated with gefitinib (11)(12)(13). Therefore, we investigated the clinical significance of the pre-treatment serum levels of CEA and CYFRA 21-1 in advanced NSCLC patients who were treated with gefitinib or erlotinib.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Jung

Kim

Lee

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The prognostic and predictive value of pre-treatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. Pre-treatment CEA and CYFRA 21-1 levels were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma and non-smokers. Low CYFRA 21-1 levels (l-CYFRA 21-1) were significantly associated with a good performance status (ECOG PS 0-

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Jung

Kim

Lee

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Japanese scholars found patients with elevated serum CEA levels had better effect to gefitinib. The patients of high serological CEA levels had higher EGFR mutation rate in recurrent lung adenocarcinoma patients after surgery, and the higher level of serological CEA, the higher mutation rate at EGFR gene (Okamoto et al, 2005). But the specimens for gene test were surgical specimens before disease recurrence, and may not representative all biological characteristic of recurrent tumor (Han et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…Currently there are several markers considered to predict the efficacy of EGFR-TKI, such as carcinoembryonic antigen (CEA) (Okamoto et al, 2005), polypeptide specific antigen (TPS) (Chen et al, 2010), amphiregulin and transforming growth factor-α (TGF-α) (Addison et al, 2010). and CEA was studied mostly and found to predict the efficacy of TKI (Okamoto et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

Pan

Hou²,

Zhang³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas

Fukushima

Yoshino

Yano³

et al. 2007

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND. The presence of epidermal growth factor receptor (EGFR) gene mutations is a good indicator of the clinical efficacy of gefitinib in patients with nonsmall cell lung cancer. It was recently reported that the serum carcinoembryonic antigen (CEA) level could be a predictive factor for the efficacy of gefitinib treatment; therefore, it is suggested that the EGFR gene mutation is associated with the serum CEA level. The current study analyzed the association between EGFR gene mutations and clinical features, including the serum CEA level, in patients with recurrent lung adenocarcinomas. METHODS. A total of 48 lung adenocarcinoma patients with postoperative disease recurrence who underwent chemotherapy were investigated. EGFR gene mutations at exons 18, 19, and 21 were measured using surgical specimens taken from the primary tumor. RESULTS. Mutations of the EGFR gene were detected in 25 of the 48 patients and the abnormal serum CEA concentration at the time of disease recurrence was found to be significantly associated with the incidence of EGFR gene mutations (P 5 .045). The rate of EGFR gene mutations significantly increased as the serum CEA level increased (serum CEA level; <5 vs 5 <20 vs 20 5 35% vs 55% vs 87.5%, respectively, P 5 .040). A multivariate analysis revealed that a higher serum CEA level at the time of disease recurrence is independently associated with EGFR gene mutations (P 5 .036) with an odds ratio of 4.70 (95% confidence interval, 1.1-21.1). CONCLUSIONS. The serum CEA level appears to be closely associated with the presence of EGFR gene mutations in patients with pulmonary adenocarcinomas.

show abstract

Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer

Cited by 52 publications

References 14 publications

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas

Contact Info

Product

Resources

About